PTC Therapeutics, Inc. (PTCT)
- Previous Close
37.66 - Open
38.06 - Bid 37.52 x 200
- Ask 37.62 x 200
- Day's Range
37.23 - 38.06 - 52 Week Range
17.53 - 40.69 - Volume
775,077 - Avg. Volume
572,793 - Market Cap (intraday)
2.895B - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-6.30 - Earnings Date Oct 24, 2024 - Oct 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
38.85
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
www.ptcbio.comRecent News: PTCT
View MorePerformance Overview: PTCT
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTCT
View MoreValuation Measures
Market Cap
2.90B
Enterprise Value
2.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.17
Price/Book (mrq)
--
Enterprise Value/Revenue
2.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-53.25%
Return on Assets (ttm)
-7.39%
Return on Equity (ttm)
--
Revenue (ttm)
900.45M
Net Income Avi to Common (ttm)
-479.52M
Diluted EPS (ttm)
-6.30
Balance Sheet and Cash Flow
Total Cash (mrq)
1.09B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-84.33M